API reference
Pretomanid
- CAS number
- 187235-37-6
- Molecular formula
- C14H12F3N3O5
- Molecular weight
- 359.26 g/mol
About this molecule
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens. Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB. It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious and shorter duration of treatment with fewer drugs.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
- InChIKey
- ZLHZLMOSPGACSZ-NSHDSACASA-N
- SMILES
- C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
- PubChem CID
- 456199
Also known as
Pretomanid · PA-824 · PA 824 · PA824 · pretomanidum · PA824 cpd · (S)-PA 824 · Pretomanid (Standard)
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.